AstraZeneca says Phase 3 trials on COVID antibody treatment confirm efficacy

0
90

AstraZeneca PLC said Thursday that Phase 3 trials on its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic Covid-19.

The pharmaceutical company AZN UK:AZN said the analysis of its continuing trial evaluating a median six months of participant follow-up revealed that one dose of AZD7442 showed 83% reduced symptomatic Covid-19 risk and no severe disease or deaths.

A…

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleCathie Wood’s ARK pounces on Roku after analyst downgrade
Next articleDow Jones Newswires: AstraZeneca: Studies show antibody reduces COVID risk

LEAVE A REPLY

Please enter your comment!
Please enter your name here